SureTrader
Interactive Brokers Advertisement
Home > Boards > US Listed > Biotechs > Viking Therapeutics, Inc. (VKTX)

I wasn't suggesting you are trying to influence

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Titan V Member Profile
 
Followed By 31
Posts 3,379
Boards Moderated 1
Alias Born 01/29/12
160x600 placeholder
Current Report Filing (8-k) "Edgar (US Regulatory)" - 12/11/2017 4:26:56 PM
Viking Therapeutics Announces Closing of Public Offering of Common Stock "PR Newswire (US)" - 12/11/2017 4:15:00 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) "Edgar (US Regulatory)" - 12/7/2017 4:40:46 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 12/7/2017 6:04:54 AM
Viking Therapeutics Announces Pricing of $12.8 Million Public Offering of Common Stock "PR Newswire (US)" - 12/6/2017 8:08:00 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) "Edgar (US Regulatory)" - 12/5/2017 4:30:49 PM
Viking Therapeutics Announces Proposed Public Offering of Common Stock "PR Newswire (US)" - 12/5/2017 4:18:00 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 11/28/2017 7:08:18 AM
Viking Therapeutics Announces Positive Top-Line Results from Phase 2 Study of VK5211 in Patients Recovering from Hip Fracture "PR Newswire (US)" - 11/28/2017 7:02:00 AM
Investor Expectations to Drive Momentum within Vector Group, NovoCure, ORBCOMM, Ecolab, Bank of America, and Viking Therapeut... "GlobeNewswire Inc." - 11/20/2017 8:20:00 AM
Quarterly Report (10-q) "Edgar (US Regulatory)" - 11/8/2017 5:12:26 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 11/8/2017 4:13:01 PM
Viking Therapeutics Reports Third Quarter 2017 Financial Results and Provides Corporate Update "PR Newswire (US)" - 11/8/2017 4:05:00 PM
Viking Therapeutics to Report Financial Results for Third Quarter 2017 on November 8, 2017 "PR Newswire (US)" - 11/1/2017 7:30:00 AM
Notice of Effectiveness (effect) "Edgar (US Regulatory)" - 10/27/2017 6:02:23 AM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) "Edgar (US Regulatory)" - 10/26/2017 4:54:21 PM
Viking Therapeutics Presents Results from In Vivo Study of VK2809 in Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH) at... "PR Newswire (US)" - 10/24/2017 7:05:00 AM
Viking Therapeutics Presents Results from Proof-of-Concept Study of VK0214 in In Vivo Model of X-Linked Adrenoleukodystrophy ... "PR Newswire (US)" - 10/23/2017 7:05:00 AM
Securities Registration Statement (s-1) "Edgar (US Regulatory)" - 10/17/2017 4:49:11 PM
Viking Therapeutics Announces Top-Line Results from Proof-of-Concept Study of VK0214 in In Vivo Model of X-Linked Adrenoleuko... "PR Newswire (US)" - 10/4/2017 7:05:00 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) "Edgar (US Regulatory)" - 9/29/2017 4:46:11 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 9/29/2017 7:06:35 AM
Viking Therapeutics Announces Purchase Agreements for up to $16.25 Million with Lincoln Park Capital "PR Newswire (US)" - 9/29/2017 7:05:00 AM
Viking Therapeutics to Host Key Opinion Leader Event to Discuss Musculoskeletal Therapeutics in Hip Fracture and Other Settin... "PR Newswire (US)" - 9/25/2017 7:30:00 AM
Viking Therapeutics Announces Results of Gene Expression Analysis from In Vivo Study of VK2809 in Non-Alcoholic Steatohepatit... "PR Newswire (US)" - 9/11/2017 7:05:00 AM
Titan V   Thursday, 10/05/17 02:22:04 PM
Re: zoomlik post# 734
Post # of 1141 
I wasn't suggesting you are trying to influence the stock price, was just curious if that influenced your point of view. Speaking of facts, off label SARM usage has seen success with pro-athletes and bodybuilders. I personally don't think it will fail, even with the older patients. Another fact is the volume in recent days and the recovery in share price. I don't think again, that a catalyst that's due in Q1/Q2 2018 is driving this instead of one that's due this quarter.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist